Answers are grounded in this paper and cite their sources.
BackgroundThe American Society of Clinical Oncology (ASCO) launched the Quality Oncology Practice Initiative (QOPI) program in 2010 to promote quality cancer care.The association has subsequently infuenced the use of neurokinin 1 (NK-1) receptor antagonists through articles published in peer-reviewed publications and its Choosing Wisely campaign.Objective To explore the rationale behind the use of NK-1 receptor antagonists in clinical practice.Methods We distributed an anonymous 12-question online survey to 650 medical oncologists in 5 states, inquiring about their use of these agents.A total of 155 responses were analyzed.Results QOPI-certifed physicians were signifcantly more likely than noncertifed physicans to use NK-1 receptor antagonists with moderately emetogenic regimens, including weekly cisplatin for head and neck cancer (82.6% vs 27.0%, respectively; P < .001),cervical and bladder cancer (81.4% vs 32.7%, P < .001),and with CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone) with or without rituxinab in lymphoma (81.4 vs 17.3%, P < .001).The majority of QOPI-certifed physicians reported using these agents for the sole purpose of maintaining QOPI certifcation (80.0%-86.0%).Certifed physicians were also signifcantly more likely to appropriately prescribe NK-1 antagonists with highly emetogenic chemotherapy.Limitations Responder bias; short survey that precludes detailed analysis; small sample size may limit generalizability to the feld of medical oncology.Conclusion Our data demonstrate that providers in QOPI-certifed practices are signifcantly more likely than those in noncertifed practices to prescribe NK-1 receptor antagonists.Certifed physicians report that satisfying ASCO-QOPI requirements is their primary motivation for offering these agents.
No takes yet. Share an insight, caveat, or question.
Nair et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: